These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis. Danahay HL; Lilley S; Fox R; Charlton H; Sabater J; Button B; McCarthy C; Collingwood SP; Gosling M Am J Respir Crit Care Med; 2020 Apr; 201(8):946-954. PubMed ID: 31898911 [No Abstract] [Full Text] [Related]
14. New horizons in the treatment of cystic fibrosis. Cuthbert AW Br J Pharmacol; 2011 May; 163(1):173-83. PubMed ID: 21108631 [TBL] [Abstract][Full Text] [Related]
15. Compartmentalized crosstalk of CFTR and TMEM16A (ANO1) through EPAC1 and ADCY1. Lérias J; Pinto M; Benedetto R; Schreiber R; Amaral M; Aureli M; Kunzelmann K Cell Signal; 2018 Apr; 44():10-19. PubMed ID: 29331508 [TBL] [Abstract][Full Text] [Related]
16. Alternative chloride transport pathways as pharmacological targets for the treatment of cystic fibrosis. Quesada R; Dutzler R J Cyst Fibros; 2020 Mar; 19 Suppl 1():S37-S41. PubMed ID: 31662238 [TBL] [Abstract][Full Text] [Related]
17. Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport. Li H; Salomon JJ; Sheppard DN; Mall MA; Galietta LJ Curr Opin Pharmacol; 2017 Jun; 34():91-97. PubMed ID: 29065356 [TBL] [Abstract][Full Text] [Related]